Literature DB >> 12354573

The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels.

Simon Akerman1, David J Williamson, Holger Kaube, Peter J Goadsby.   

Abstract

Migraine is characteristically accompanied by a throbbing quality of head pain thought to involve trigeminovascular afferents. Administration of nitric oxide (NO) donors provides the most reliable model of migraine induction in humans. The present studies used intravital microscopy to monitor the effect of local meningeal nerve stimulation and NO on dural blood vessels and any modulation of that effect by anti-migraine compounds. NO caused an immediate and reproducible dilation of meningeal blood vessels that was partially blocked by sumatriptan and indomethacin, while flunarizine and histamine H(1) and H(2) receptor antagonists were unable to block the dilation. Indomethacin also inhibited the neurogenic dilation while flunarizine did not. The present studies demonstrate that NO is unlikely to interact with histamine to produce its dilatory response. Sumatriptan and indomethacin inhibit the NO response by inhibiting trigeminal activation and calcitonin gene-related peptide (CGRP) release. Flunarizine does not modify either the neurogenic vasodilator response or the NO meningeal dilator response at least acutely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354573     DOI: 10.1016/s0014-2999(02)02307-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  Diencephalic and brainstem mechanisms in migraine.

Authors:  Simon Akerman; Philip R Holland; Peter J Goadsby
Journal:  Nat Rev Neurosci       Date:  2011-09-20       Impact factor: 34.870

3.  The effect of sumatriptan on nitric oxide synthase enzyme production after iatrogenic inflammation in the brain stem of adolescent rats: A randomized, controlled, experimental study.

Authors:  Savas Demirpence; Semra Hiz Kurul; Müge Kiray; Kazim Tugyan; Osman Yilmaz; Galip Köse
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

Review 4.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

6.  A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Peter J Goadsby
Journal:  J Headache Pain       Date:  2010-10-27       Impact factor: 7.277

7.  Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura.

Authors:  Umberto Pietrini; Massimo De Luca; Enrico Del Bene; Francesco De Cesaris; Luca Bertinotti; Nicola Colangelo; Alberto Moggi Pignone
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

Review 8.  Mechanism of action of indomethacin in indomethacin-responsive headaches.

Authors:  Oliver Summ; Stefan Evers
Journal:  Curr Pain Headache Rep       Date:  2013-04

9.  Patients with migraine with aura have increased flow mediated dilation.

Authors:  Fabrizio Vernieri; Leo Moro; Claudia Altamura; Paola Palazzo; Raffaele Antonelli Incalzi; Paolo Maria Rossini; Claudio Pedone
Journal:  BMC Neurol       Date:  2010-03-10       Impact factor: 2.474

Review 10.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.